Galili, 1997 - Google Patents
The α-Galactosyl Epitope (Galα1-3Ga1β1-4GIcNAc-R) and the Natural Anti-Gal AntibodyGalili, 1997
- Document ID
- 10926968800987825317
- Author
- Galili U
- Publication year
- Publication venue
- Molecular Biology and Evolution of Blood Group and MHC Antigens in Primates
External Links
Snippet
The carbohydrate structure GalaI-3Gal~ 1-4GlcNAc-R (termed the a-galactosyl epitope) and the natural antibody which interacts specifically with this epitope (termed anti-Gal) display a unique pattern of distribution in primates. The a-galactosyl epitope is abundantly expressed …
- 102000004965 antibodies 0 title abstract description 46
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
- A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Galili | Evolution and pathophysiology of the human natural anti-α-galactosyl IgG (anti-Gal) antibody | |
| Galili | The α‐gal epitope and the anti‐Gal antibody in xenotransplantation and in cancer immunotherapy | |
| Cooper | Xenoantigens and xenoantibodies | |
| Naiki et al. | Immunochemical study of the human blood group P1, P, and Pk glycosphingolipid antigens | |
| Holgersson et al. | Characteristics of protein–carbohydrate interactions as a basis for developing novel carbohydrate‐based antirejection therapies | |
| LaTemple et al. | Synthesis of α-galactosyl epitopes by recombinant α1, 3galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose | |
| Tanemura et al. | Differential immune responses to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation | |
| Nyame et al. | Schistosoma mansoniInfection in Humans and Primates Induces Cytolytic Antibodies to Surface LexDeterminants on Myeloid Cells | |
| EP0661980B1 (en) | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients | |
| EP2088864B1 (en) | Selective immunodepletion of endogenous stem cell niche for engraftment | |
| US5928647A (en) | Inducing cytotoxic T lymphocyte responses | |
| Galili | The natural anti-Gal antibody as foe turned friend in medicine | |
| Garratty | Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs | |
| Galili et al. | The natural anti-Gal antibody | |
| JP5192020B2 (en) | Use of mannose receptor-bearing antigen-presenting cells in the manufacture of a medicament for inducing a cytotoxic T cell response to an antigen | |
| JP2735947B2 (en) | Idiotype vaccination against B-cell lymphoma | |
| Galili | Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics? | |
| Silberstein et al. | The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells | |
| Galili | Evolution of α1, 3Galactosyltransferase and of the α-Gal Epitope | |
| CN1149224C (en) | Monoclonal antibody for recognizing N-glycolyl-galactose-glucosialyl oligosaccharide in malignant tumors and composition containing the same | |
| Galili | Antibody production and tolerance to the α-gal epitope as models for understanding and preventing the immune response to incompatible ABO carbohydrate antigens and for α-gal therapies | |
| Henion et al. | Synthesis of α-gal epitopes on influenza virus vaccines, by recombinant α1, 3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody | |
| Manches et al. | Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells | |
| Galili | The α-Galactosyl Epitope (Galα1-3Ga1β1-4GIcNAc-R) and the Natural Anti-Gal Antibody | |
| Watarai et al. | Application of liposomes to generation of monoclonal antibody to glycosphingolipid: production of monoclonal antibody to GgOse4Cer |